. 2022 Feb 16;59:101597. doi: 10.1016/j.smim.2022.101597

Table 1.

Resolvins^*, SPMs and Eicosanoids in Human Subjects with COVID-19 Infections.

Reference	Findings	Source
Schwarz et al. [31]	Dysregulation of eicosanoids increases 5-lipoxygenase, leukotriene, prostaglandins, EETs, specific resolvins in severe illness, decreases 12-LOX (ALOX12) and COX-2; immune lipid mediator metabolome imbalance in severe COVID-19	Serum
Archambault et al. [23]	Predominance of prostaglandins, thromboxane, LTB₄ and leukotrienes; increased lipoxin A₄ and D-series resolvins	Bronchoalveolar lavages (BAL)
Archambault et al. [23]	Proinflammatory eicosanoids and SPMs were elevated in COVID-19 BAL	Bronchoalveolar lavages (BAL)
Koenis et al. [25]	Disrupted resolution and altered phagocyte responses	Plasma
Koenis et al. [25]	SPM and eicosanoids identified	Plasma
Turnbull et al. [26]	SPM and eicosanoid metabolomes identified in critically ill COVID-19 showing dysregulation during infection	Serum
Arnardottir et al. [195]	Omega-3 in resolution of COVID-19; randomized clinical trial	COVID-Omega-F

The potential for resolvins and other SPMs as new therapeutic approaches in the resolution of inflammation was recognized early by inflammation experts [196] from the time of their initial discovery; see [197].